Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (3698)	1/31/1998 1:42:00 AM
From: JOHN W.	Read Replies (1) \| Respond to of 6136

"Treatment of HIV-1-Associated Microsporidiosis and Cryptosporidiosis With Combination Antiretroviral Therapy (Early Report)" Lancet (01/24/98) Vol. 351, No. 9098, P. 256; Carr, Andrew; Marriott, Deborah; Field, Andrew; et al. Australian researchers have determined that combination antiretroviral therapy that includes a protease inhibitor can aid in the treatment of HIV-1 related Enterocytozoon bieneusi and Cryptosporidium parvum. The bacteria can induce microsporidiosis and cryptosporidiosis infections in the gastrointestinal tracts of HIV-1-infected individuals, causing persistent diarrhea, weight loss, and abdominal pain. The scientists administered medical regimens of combination therapy that included at least one HIV-1 protease inhibitor to five patients with microsporidiosis, three with cryptosporidiosis, and one with both infections; all nine men were infected with HIV. The researchers saw complete clinical responses in all nine subjects, who gained an average of 15 kg in weight and ceased taking all antidiarrheal and antimicrobial treatments. Moreover, follow-up stool microscopy found that eight of eight men tested showed neither pathogen, while all five patients tested by endoscopy were also negative for the pathogens. Five of the nine patients remained symptom free for an average of 13 months, while four of the patients had recurring diarrhea between seven and 13 months. The researchers noted that while neither infection was eliminated, combination that includes an HIV-1 protease inhibitor can effect "complete and sustained clinical, microbiological, and histological resolution of HIV-1-associated opportunistic infections."